Completed PHASE2 INTERVENTIONAL NCT01472770

A Phase II Study of Gemcitabine and Capecitabine for Treatment Resistant, Metastatic Colorectal Cancer (GemCaP)

Sponsor: Vejle Hospital

Interventions Gemcitabine + Capecitabine

Updated 5 times since 2017 Last updated: Dec 3, 2014 Started: Oct 31, 2011 Primary completion: May 31, 2013 Completion: May 31, 2014

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Metastatic Colorectal Cancer, this trial is completed. The trial is conducted by Vejle Hospital and has accumulated 5 data snapshots since 2011. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Oct 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Vejle Hospital

Data source: Vejle Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Vejle, Denmark